drugset / Trial / NCT00778375
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Phase 2
Completed
122 enrolled
M.D. Anderson Cancer Center
Eisai Inc. · collabGenzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older. The safety of this treatment will also be studied.
Timeline
- Start
- 2008-10
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 20 mg | Subcutaneous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |